Header Ads Widget

Responsive Advertisement



India's first coronavirus vaccine COVAXIN human trials begin today at AIIMS, Delhi. All you need to know about.

After a green signal from the AIIMS Ethics Committee at Delhi, COVAXIN human trials are beginning today at AIIMS, Delhi. COVAXIN is an indigenously developed COVID-19 vaccine by Bharat Biotech, Which is developed with the collaboration of the Indian Council of Medical Research (ICMR). The vaccine received its approval by the Drugs Controller General of India (DCGI) for Phase I and Phase II begins today after got a nod from the AIIMS Ethics Committee.
The Indian Council of Medical Research (ICMR) selected 12 sites including AIIMS, Delhi for conducting Phase I and II human trials for covaxin. In Phase I, 375 volunteers tested from this vaccine and the maximum number of people 100 from the AIIMS, Delhi.

Healthy volunteers that have no history of COVID-19 and aged more than 18 years & less than 55 years, would be eligible to take part in the trial, double-blind, placebo-controlled clinical trial. The Professor of the Centre for Community Medicine (CCM) Dr. Sanjay Rai at AIIMS said. The AIIMS Ethics Committee gave its nod for a human clinical trial to begin today. Anybody who wants to participate in the trial can send an email to Ctaiims.covid19@gmail.com or an SMS to or call on 7428847499, he said.

Human Trials of COVAXIN has begun at AIIMS Patna and some more sites. 10 volunteers chosen to start a human trial. All India Institute of Medical Sciences (AIIMS) will start the screening of the individuals and evaluate their health condition from today onwards before vaccinating them.

Covaxin has been derived from a strain of the novel coronavirus isolated by the National Institute of Virology (NIV) in Pune. Bharat Biotech international limited (BBIL) developed an “inactivated" vaccine at its high-containment facility at Genome Valley in Hyderabad, developed in collaboration with the Indian Council of Medical Research (ICMR).

The Drugs Controller General of India (DCGI) has permitted two vaccines -- one developed by the Bharat Biotech International Limited (BBIL) in collaboration with the  Indian Council of Medical Research and another one by Cadila Healthcare Ltd. for phase I and II human clinical trials of COVAXIN.

Two vaccine candidates have undergone successful toxicity studies in rats, mice, and rabbits, and these data were submitted to Drugs Controller General of India (DCGI) following which both got clearance to start the early phase human trials. Approximately 1,000 human volunteers would be participating in the trials for each of the two indigenously developed vaccine candidates, he had said.

Post a Comment